Whereas loss-of-function mutations of TRAF2 or cIAP2 have been described in MCL and DLBCL, inactivating mutations or homozygous deletions of the gene encoding TRAF3 have been reported in HL (15% of cases), DLBCL (15%), and in multiple myeloma (50%) [9,19,20,23,45,160,170,172]. This evidence concerns the gene BIRC3 and mantle cell lymphoma.